42 related articles for article (PubMed ID: 6436416)
1. Studies on human antihemophilic factor. Evidence for a covalently linked subunit structure.
Switzer ME; McKee PA
J Clin Invest; 1976 Apr; 57(4):925-37. PubMed ID: 1084890
[TBL] [Abstract][Full Text] [Related]
2. Some effects of calcium on the activation of human factor VIII/Von Willebrand factor protein by thrombin.
Switzer ME; McKee PA
J Clin Invest; 1977 Oct; 60(4):819-28. PubMed ID: 408379
[TBL] [Abstract][Full Text] [Related]
3. Effects of thrombin treatment of preparations of factor VIII and the Ca2+-dissociated small active fragment.
Cooper HA; Reisner FF; Hall M; Wagner RH
J Clin Invest; 1975 Sep; 56(3):751-60. PubMed ID: 1080490
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
5. Characterization of proteases in AHF concentrates: effect on factor VIII:von Willebrand protein as assessed by high-pressure gel permeation chromatography.
Orthner CL
J Lab Clin Med; 1984 Nov; 104(5):816-28. PubMed ID: 6436416
[TBL] [Abstract][Full Text] [Related]
6. Formation of the fibrin clot: the balance of procoagulant and inhibitory factors.
Lämmle B; Griffin JH
Clin Haematol; 1985 Jun; 14(2):281-342. PubMed ID: 2994929
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
Budde U; Metzner HJ; Müller HG
Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
[TBL] [Abstract][Full Text] [Related]
8. Synthetic peptide substrates in hemostatic testing.
Fareed J; Messmore HL; Walenga JM; Bermes EW
Crit Rev Clin Lab Sci; 1983; 19(2):71-134. PubMed ID: 6373139
[TBL] [Abstract][Full Text] [Related]
9. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
Michiels JJ; Budde U; van der Planken M; van Vliet HH; Schroyens W; Berneman Z
Best Pract Res Clin Haematol; 2001 Jun; 14(2):401-36. PubMed ID: 11686107
[TBL] [Abstract][Full Text] [Related]
10. [Factor VIII/von Willebrand factor complex (FVIII/vWF)].
Yoshioka A
Rinsho Byori; 1985 Feb; Spec No 61():73-85. PubMed ID: 3923232
[No Abstract] [Full Text] [Related]
11. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
